Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Baseline characteristics of diabetic and non-diabetic patients. Variable | Diabetes Group(n = 753) | Non-Diabetes Group(n = 1878) | p-Value: Vitamin D ng/mL, mean (SD) | 14.7 (SD 17.2) | 15.6 (SD 7.9) | 0.634

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case-control study.

Case-control study

Compares people with an outcome against people without it, examining exposures.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Impact of Sarcopenic Diabetes on Outcomes and Mortality in Older Adults Hospitalized for Hip Fracture: A Nested Case: Control Study Within a Real-World Evidence Cohort

Source: Article title.

All diabetic patients aged 70 years or older hospitalized with hip fracture during the recruitment period were considered as cases, and hip fracture patients without diabetes hospitalized with hip fracture were included in the control group.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Impact of Sarcopenic Diabetes on Outcomes and Mortality in Older Adults Hospitalized for Hip Fracture: A Nested Case-Control Study Within a Real-World Evidence Cohort

Case-control study · Nutrients · 2025

Original publication title

Impact of Sarcopenic Diabetes on Outcomes and Mortality in Older Adults Hospitalized for Hip Fracture: A Nested Case: Control Study Within a Real-World Evidence Cohort

Elisa García-Tercero; Daniela Villalon Rubio; Ángel Belenguer-Varea; Cristina Cunha-Pérez; José Viña; Francisco José Tarazona-Santabalbina

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Background: This study addresses the prevalence and outcomes of sarcopenic diabetes among older adults hospitalized for hip fractures, highlighting its association with nutritional status, frailty, in-hospital outcomes, and mortality. With the global incidence of hip fractures anticipated to rise significantly, understanding these associations is crucial, especially considering the higher prevalence of sarcopenia in diabetic patients, which exacerbates outcomes. Methods: An observational, unicentric case: control study nested within a real-world data cohort was conducted. It included 2631 older adults (aged ≥ 70 years) hospitalized for hip fractures at the Hospital Universitario de la Ribera, Spain, from 2014 to 2021.

Diabetic patients were classified as cases, and non-diabetic patients served as controls. The study examined demographic variables, comorbidities, nutritional status, geriatric syndromes, and mortality, using the SARC-F questionnaire for sarcopenia screening. Results: The study found that cases (diabetic patients) presented with higher comorbidities, longer hospital stays, and a higher prevalence of sarcopenia, significantly impacting in-hospital and long-term mortality rates. The prevalence of possible sarcopenia was notably higher at 61.5% among diabetic patients. Sarcopenia was strongly correlated with worse functional outcomes and higher mortality.

Conclusions: Sarcopenic diabetes significantly increases the risk of adverse outcomes and mortality in older adults with hip fractures. The findings underscore the importance of routine screening for diabetes and sarcopenia in this patient population to mitigate risks and improve rehabilitation outcomes.

Authors’ abstract

Background: This study addresses the prevalence and outcomes of sarcopenic diabetes among older adults hospitalized for hip fractures, highlighting its association with nutritional status, frailty, in-hospital outcomes, and mortality. With the global incidence of hip fractures anticipated to rise significantly, understanding these associations is crucial, especially considering the higher prevalence of sarcopenia in diabetic patients, which exacerbates outcomes. Methods: An observational, unicentric case: control study nested within a real-world data cohort was conducted. It included 2631 older adults (aged ≥ 70 years) hospitalized for hip fractures at the Hospital Universitario de la Ribera, Spain, from 2014 to 2021.

Diabetic patients were classified as cases, and non-diabetic patients served as controls. The study examined demographic variables, comorbidities, nutritional status, geriatric syndromes, and mortality, using the SARC-F questionnaire for sarcopenia screening. Results: The study found that cases (diabetic patients) presented with higher comorbidities, longer hospital stays, and a higher prevalence of sarcopenia, significantly impacting in-hospital and long-term mortality rates. The prevalence of possible sarcopenia was notably higher at 61.5% among diabetic patients. Sarcopenia was strongly correlated with worse functional outcomes and higher mortality.

Conclusions: Sarcopenic diabetes significantly increases the risk of adverse outcomes and mortality in older adults with hip fractures. The findings underscore the importance of routine screening for diabetes and sarcopenia in this patient population to mitigate risks and improve rehabilitation outcomes.

Publication and source details

Original title: Impact of Sarcopenic Diabetes on Outcomes and Mortality in Older Adults Hospitalized for Hip Fracture: A Nested Case: Control Study Within a Real-World Evidence Cohort

Elisa García-Tercero; Daniela Villalon Rubio; Ángel Belenguer-Varea; Cristina Cunha-Pérez; José Viña; Francisco José Tarazona-Santabalbina

Nutrients · 2025

* Correspondence: egtercero@sescam.jccm.es© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Abbott LaboratoriesAB29042024The project was funded by Abbott Laboratories with the funding number AB29042024.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:26:11.808739+00:00

DOI: 10.3390/nu17162616 · PMC12389665